As the director of the Gamaleya Center, Alexander Gintsburg, said earlier, the drug for coronavirus based on monoclonal antibodies, which is being developed at the center, is planned to be used on the third or fourth day after the patient is admitted to the hospital with COVID-19.
Doctor of Biological Sciences, Professor of the Department of Virology, Faculty of Biology, Moscow State University Alexei Agranovsky, in an interview with NSN, spoke about immunity in those who had been ill with Omicron.